Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;22(2):121-31.
doi: 10.1089/jwh.2012.3479.

Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study

Susan G Kornstein  1 , Marisa Toups, A John Rush, Stephen R Wisniewski, Michael E Thase, James Luther, Diane Warden, Maurizio Fava, Madhukar H Trivedi
Affiliations

Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study

Susan G Kornstein et al. J Womens Health (Larchmt). 2013 Feb.

Abstract

Background: Menopausal status and use of hormonal contraception or menopausal hormone therapy (HT) may affect treatment response to selective serotonin reuptake inhibitors (SSRIs). This report evaluates whether menopausal status and use of hormonal contraceptives or menopausal HT affect outcome in women treated with citalopram.

Methods: In the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, 896 premenopausal and 544 postmenopausal women were treated with citalopram for 12-14 weeks. Baseline demographic and clinical characteristics were used in adjusted analysis of the effect of menopausal status and use of hormonal contraceptives or menopausal HT on outcomes. Remission was defined as final Hamilton Rating Scale for Depression-17 (HRSD(17)) ≤7 or Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR(16)) score ≤5 and response as ≥50% decrease from the baseline QIDS-SR(16) score.

Results: Premenopausal and postmenopausal women differed in multiple clinical and demographic baseline variables but did not differ in response or remission rates. Premenopausal women taking hormonal contraceptives had significantly greater unadjusted remission rates on the HRSD(17) and the QIDS-SR(16) than women not taking contraception. Response and remission rates were not different between postmenopausal women taking vs. not taking HT. Adjusted results showed no significant difference in any outcome measure across menopause status in women who were not taking contraception/HT. There were no significant differences in adjusted results across HT status in premenopausal or postmenopausal women.

Conclusions: In this study, citalopram treatment outcome was not affected by menopausal status. Hormonal contraceptives and HT also did not affect probability of good outcome.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Consort chart. Distribution of menopausal status and hormone therapy. Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. HRSD, Hamilton Rating Scale for Depression.
See this image and copyright information in PMC

References

    1. Kessler RC. Epidemiology of women and depression. J Affect Disord. 2003;74:5–13. - PubMed
    1. Michaud CM. Murray CJL. Bloom BR. Burden of disease—implications for future research. JAMA. 2001;285:535–539. - PubMed
    1. Kornstein SG. Schatzberg AF. Thase ME, et al. Gender differences in chronic major and double depression. J Affect Disord. 2000;60:1–11. - PubMed
    1. Marcus SM. Young EA. Kerber KB, et al. Gender differences in depression: Findings from the STAR*D study. J Affect Disord. 2005;87:141–150. - PubMed
    1. Marcus SM. Kerber K. Rush AJ, et al. Gender differences in depression symptoms in treatment seeking adults: STAR*D confirmatory analyses. Compr Psychiatry. 2008;49:238–246. - PMC - PubMed

Publication types

MeSH terms

Substances